ATE464054T1 - Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon - Google Patents

Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon

Info

Publication number
ATE464054T1
ATE464054T1 AT06754274T AT06754274T ATE464054T1 AT E464054 T1 ATE464054 T1 AT E464054T1 AT 06754274 T AT06754274 T AT 06754274T AT 06754274 T AT06754274 T AT 06754274T AT E464054 T1 ATE464054 T1 AT E464054T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
neuroactive steroid
pregnan
methoxymethyl
imidazolyl
Prior art date
Application number
AT06754274T
Other languages
English (en)
Inventor
Richard M Woodward
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE464054T1 publication Critical patent/ATE464054T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06754274T 2005-06-09 2006-06-09 Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon ATE464054T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68890505P 2005-06-09 2005-06-09
PCT/EP2006/005574 WO2006131392A1 (en) 2005-06-09 2006-06-09 Pharmaceutical compositions of a neuroactive steroid and uses thereof

Publications (1)

Publication Number Publication Date
ATE464054T1 true ATE464054T1 (de) 2010-04-15

Family

ID=36790861

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10000305T ATE538797T1 (de) 2005-06-09 2006-06-09 Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon
AT06754274T ATE464054T1 (de) 2005-06-09 2006-06-09 Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT10000305T ATE538797T1 (de) 2005-06-09 2006-06-09 Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon

Country Status (25)

Country Link
US (2) US20090131383A1 (de)
EP (3) EP1888080B1 (de)
JP (2) JP2008542419A (de)
KR (3) KR20120028407A (de)
CN (1) CN101193640A (de)
AT (2) ATE538797T1 (de)
AU (1) AU2006256851C1 (de)
BR (1) BRPI0612921A2 (de)
CA (1) CA2611430C (de)
CY (2) CY1110199T1 (de)
DE (1) DE602006013622D1 (de)
DK (2) DK2168585T3 (de)
EA (1) EA013744B1 (de)
ES (2) ES2344313T3 (de)
HR (2) HRP20100372T1 (de)
IL (3) IL187813A (de)
NO (1) NO20076319L (de)
NZ (1) NZ562979A (de)
PL (2) PL2168585T3 (de)
PT (2) PT1888080E (de)
RS (2) RS51304B (de)
SI (2) SI1888080T1 (de)
UA (1) UA94909C2 (de)
WO (1) WO2006131392A1 (de)
ZA (1) ZA200709188B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3572417B1 (de) 2011-10-14 2025-12-17 Sage Therapeutics, LLC 3,3-disubstituierte 19-nor-pregnan verbindungen, zusammensetzungen damit und verwendungen davon
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
EP2986624B1 (de) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. Neuroaktive 19-nor-steroide zur verwendung zur behandlung von krankheiten
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ME03809B (de) 2014-10-16 2021-04-20 Sage Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von störungen des zentralen nervensystems
CN117024501A (zh) * 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
EP4155314A1 (de) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroaktive steroide, zusammensetzungen und verwendungen davon
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
MX2021006985A (es) * 2018-12-14 2021-09-08 Praxis Prec Medicines Inc Metodos para el tratamiento de la depresión.
MX2021007142A (es) * 2018-12-17 2021-08-11 Intra Cellular Therapies Inc Compuestos organicos.
US20220125803A1 (en) * 2019-03-04 2022-04-28 Praxis Precision Medicines, Inc. Methods for the treatment of perimenopause and menopause
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
JP2022552808A (ja) * 2019-10-02 2022-12-20 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｇａｂａ－ａ受容体陽性アロステリック調節因子と、ｎｍｄａ拮抗薬、ｎｍｄａ陰性アロステリック調節因子、またはｎｍｄａ部分作動薬との組み合わせ
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
EP4294819A4 (de) 2021-02-18 2024-12-18 Praxis Precision Medicines, Inc. Hemicitratsalze von gaba-a positiven allosterischen modulatoren und deren kristallform
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
EP4329751A4 (de) * 2021-04-26 2025-03-19 Praxis Precision Medicines, Inc. Behandlungsverfahren mit neuroaktiven steroiden
WO2023159035A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE
WO2023164386A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
JP7817300B2 (ja) * 2023-02-14 2026-02-18 沢井製薬株式会社 コーティング顆粒、コーティング顆粒を含む製剤及びそれらの製造方法
WO2025059464A1 (en) * 2023-09-15 2025-03-20 Praxis Precision Medicines, Inc. Determining effect of a drug based on brain activity and a trained machine learning model

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4884909A (en) 1986-12-25 1989-12-05 Canon Kabushiki Kaisha Recording apparatus
ES2296594T3 (es) * 1994-02-14 2008-05-01 Euro-Celtique S.A. Androstanos y pregnanos para la modulacion alosterica del receptor de gaba.
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
CO5210862A1 (es) * 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
US6080736A (en) * 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one

Also Published As

Publication number Publication date
DK1888080T3 (da) 2010-07-19
RS52199B (sr) 2012-10-31
EA013744B1 (ru) 2010-06-30
RS51304B (sr) 2010-12-31
KR20100095661A (ko) 2010-08-31
AU2006256851B2 (en) 2009-12-17
EP2168585A1 (de) 2010-03-31
CY1110199T1 (el) 2015-01-14
DK2168585T3 (da) 2012-02-27
WO2006131392A1 (en) 2006-12-14
ZA200709188B (en) 2008-08-27
CA2611430C (en) 2013-09-10
JP2012229261A (ja) 2012-11-22
EP1888080A1 (de) 2008-02-20
ES2344313T3 (es) 2010-08-24
WO2006131392A8 (en) 2007-02-15
EP2263675A3 (de) 2011-05-18
PL1888080T3 (pl) 2010-09-30
DE602006013622D1 (de) 2010-05-27
CA2611430A1 (en) 2006-12-14
CY1112499T1 (el) 2015-12-09
SI2168585T1 (sl) 2012-04-30
IL187813A0 (en) 2008-08-07
IL211114A (en) 2014-04-30
ATE538797T1 (de) 2012-01-15
AU2006256851C1 (en) 2010-07-15
PT2168585E (pt) 2012-03-05
KR20120028407A (ko) 2012-03-22
HRP20120264T1 (hr) 2012-04-30
AU2006256851A1 (en) 2006-12-14
HK1140947A1 (en) 2010-10-29
BRPI0612921A2 (pt) 2010-12-07
EP2263675A2 (de) 2010-12-22
HK1118202A1 (en) 2009-02-06
IL216194A0 (en) 2012-01-31
US20120276196A1 (en) 2012-11-01
NZ562979A (en) 2010-11-26
PT1888080E (pt) 2010-07-06
SI1888080T1 (sl) 2010-08-31
UA94909C2 (ru) 2011-06-25
CN101193640A (zh) 2008-06-04
JP2008542419A (ja) 2008-11-27
EA200800007A1 (ru) 2008-04-28
PL2168585T3 (pl) 2012-05-31
EP2168585B1 (de) 2011-12-28
IL216194A (en) 2013-09-30
KR20080017091A (ko) 2008-02-25
EP1888080B1 (de) 2010-04-14
IL187813A (en) 2011-12-29
NO20076319L (no) 2007-12-07
US20090131383A1 (en) 2009-05-21
HRP20100372T1 (hr) 2010-08-31
ES2380060T3 (es) 2012-05-08

Similar Documents

Publication Publication Date Title
ATE464054T1 (de) Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon
BRPI0708038B8 (pt) derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular
GEP20115143B (en) Combination of azelastine and fluticasone
PT2038290E (pt) Moduladores de receptor do tipo toll 7
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
EP4566670A3 (de) Modulatoren der pharmakokinetischen eigenschaften von therapeutika
BRPI0517891A (pt) composições compreendendo azelastina e métodos de uso das mesmas
CO5140098A1 (es) Combinaciones de un agonista de betra-2 y un esteroide, su uso para tratamiento de enfermedades inflamatorias u obstructivas de las vias aereas
WO2005065646A3 (en) Novel drug compositions and dosage forms
AU2003207016A1 (en) Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor for the treatment of inflammatory and allergic conditions
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
EP1933785A4 (de) Zusammensetzungen, systeme, kits und verfahren zur verabreichung von rapamycin-analoga mit paclitaxel unter verwendung von medizinprodukten
BRPI0509863A (pt) liberação de fármaco para fundo de olho
FR2909284B1 (fr) Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
WO2008024485A3 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent
WO2008012338A3 (en) Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
BRPI0515103A (pt) composição farmacêutica, inalador, processos para preparar o mesmo, e uma composição farmacêutica, e, uso de uma composição farmacêutica
SE0400346D0 (sv) Steroids for cancer treatment
WO2004041190A3 (en) Composition for the treatment of macular degenration
BRPI0618370A2 (pt) formulação aerossol de medicamento, uso do mesmo e kit de inalação
NO20065657L (no) Filmformet ostriol-inneholdende medikament for oral administrasjon
CL2007001894A1 (es) Formulacion oftalmica topica que comprende: 0,1% de dexametasona, 0,3% de clorhidrato de ciprofloxacino, cloruro de sodio, 6% de hidroxipropil-beta-ciclodextrina, 0,15% de sulfato de sodio, 0,05% de edetato disodico, 0,022% de cloruro de benzalconio al 50% y 0,100ml/100ml de polisorbato 80; util para tratar infecciones oculares.
HK1131578A (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1888080

Country of ref document: EP